Receptor-Driven ERK Pulses Reconfigure MAPK Signaling and Enable Persistence of Drug-Adapted BRAF-Mutant Melanoma Cells
Open accessThe DOI matches its Crossref record; 23 of the 23 references it cites were found in a registry or an index.
Abstract
SUMMARY Anti-cancer drugs commonly target signal transduction proteins activated by mutation. In patients with BRAF V600E melanoma, small molecule RAF and MEK kinase inhibitors cause dramatic but often transient tumor regression. Emerging evidence suggests that cancer cells adapting by non-genetic mechanisms constitute a reservoir for the development of drug-resistant tumors. Here, we show that few hours after exposure to RAF/MEK inhibitors, BRAF V600E melanomas undergo adaptive changes involving disruption of negative feedback and sporadic pulsatile reactivation of the MAPK pathway, so that MAPK activity is transiently high enough in some cells to drive proliferation. Quantitative proteomics and computational modeling show that pulsatile MAPK reactivation is possible due to the co-existence in cells of two MAPK cascades: one driven by BRAF V600E that is drug-sensitive and a second driven by receptors that is drug-resistant. Paradoxically, this may account both for the frequent emergence of drug resistance and for the tolerability of RAF/MEK therapy in patients.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Improved survival with vemurafenib in melanoma with BRAF V600E mutation
Chapman, P. B., Hauschild, A., Robert, C., Haanen, J. B., Ascierto, P., Larkin, J., Dummer, R., Garbe, C., Testori, A., Maio, M., et al. (2011) · New England Journal of Medicine · doi:10.1056/nejmoa1103782 · Cited by 7,720 · cited 1×
“However, we speculate that the resistance of physiological MAPK signaling to both RAF and MEK inhibitors might explain why these drugs spare normal cells and are well tolerated in patients (Chapman et al., 2011; Flaherty et al., 2012).”
BackgroundDissecting the multicellular ecosystem of metastatic melanoma by single-cell RNA-seq
Tirosh, I., Izar, B., Prakadan, S. M., Wadsworth, M. H., Treacy, D., Trombetta, J. J., Rotem, A., Rodman, C., Lian, C., Murphy, G., et al. (2016) · Science · doi:10.1126/science.aad0501 · Cited by 4,944 · cited 1×
“Heterogeneous expression of EGFR and AXL has also been associated with drug resistance in patients (Tirosh et al., 2016; Shaffer et al., 2017).”
BackgroundSelf-citationSkyline: an open source document editor for creating and analyzing targeted proteomics experiments
MacLean, B., Tomazela, D. M., Shulman, N., Chambers, M., Finney, G. L., Frewen, B., Kern, R., Tabb, D. L., Liebler, D. C., & MacCoss, M. J. (2010) · Bioinformatics · doi:10.1093/bioinformatics/btq054 · Cited by 4,697
Unresponsiveness of colon cancer to BRAF(V600E) inhibition through feedback activation of EGFR
Prahallad, A., Sun, C., Huang, S., Di Nicolantonio, F., Salazar, R., Zecchin, D., Beijersbergen, R. L., Bardelli, A., & Bernards, R. (2012) · Nature · doi:10.1038/nature10868 · Cited by 2,051
Drug-tolerant persister cancer cells are vulnerable to GPX4 inhibition
Hangauer, M. J., Viswanathan, V. S., Ryan, M. J., Bole, D., Eaton, J. K., Matov, A., Galeas, J., Dhruv, H. D., Berens, M. E., Schreiber, S. L., et al. (2017) · Nature · doi:10.1038/nature24297 · Cited by 1,799
Tumour micro-environment elicits innate resistance to RAF inhibitors through HGF secretion
Straussman, R., Morikawa, T., Shee, K., Barzily-Rokni, M., Qian, Z. R., Du, J., Davis, A., Mongare, M. M., Gould, J., Frederick, D. T., et al. (2012) · Nature · doi:10.1038/nature11183 · Cited by 1,771 · cited 2×
“Components of the extracellular environment, including growth factors involved in autocrine/paracrine signaling, have also been shown to promote resistance (Straussman et al., 2012;Wilson et al., 2012), but how mitogenic signals are transduced is unknown: similar to many other types of mammalian cells, melanocytes req…”
BackgroundEncorafenib, Binimetinib, and Cetuximab in BRAF V600E–Mutated Colorectal Cancer
Kopetz, S., Grothey, A., Yaeger, R., Van Cutsem, E., Desai, J., Yoshino, T., Wasan, H., Ciardiello, F., Loupakis, F., Hong, Y. S., et al. (2019) · New England Journal of Medicine · doi:10.1056/nejmoa1908075 · Cited by 1,491
Rare cell variability and drug-induced reprogramming as a mode of cancer drug resistance
Shaffer, S. M., Dunagin, M. C., Torborg, S. R., Torre, E. A., Emert, B., Krepler, C., Beqiri, M., Sproesser, K., Brafford, P. A., Xiao, M., et al. (2017) · Nature · doi:10.1038/nature22794 · Cited by 1,218 · cited 7×
“Receptors levels are often correlated among neighboring cells (Shaffer et al., 2017) (Figure 3D), and this may explain why pulsing occurs in patches.”
BackgroundInfluentialWidespread potential for growth-factor-driven resistance to anticancer kinase inhibitors
Wilson, T. R., Fridlyand, J., Yan, Y., Penuel, E., Burton, L., Chan, E., Peng, J., Lin, E., Wang, Y., Sosman, J., et al. (2012) · Nature · doi:10.1038/nature11249 · Cited by 1,134 · cited 4×
“However, multiple receptors (e.g., ERBB1/2, c-MET, andFGFR) (Straussman et al., 2012;Wilson et al., 2012) are individually capable of inducing ERKpulsingwhen cognate ligands are present.”
BackgroundInfluentialAllosteric inhibition of SHP2 phosphatase inhibits cancers driven by receptor tyrosine kinases
Chen, Y.-N. P., LaMarche, M. J., Chan, H. M., Fekkes, P., Garcia-Fortanet, J., Acker, M. G., Antonakos, B., Chen, C. H.-T., Chen, Z., Cooke, V. G., et al. (2016) · Nature · doi:10.1038/nature18621 · Cited by 925 · cited 7×
“To investigate the role of RTKs in generating spontaneous ERK pulses, we treated vemurafenibadapted A375 cells (1 mM, 36 h) with inhibitors of the EGFR/ ERBB receptors (lapatinib or poziotinib), FGFR (infingratinib), or AXL (R428) at 1 mM; alternatively cells were treated with a SHP2 phosphatase inhibitor (SHP099, 5 m…”
BackgroundInfluential
Cited by
Therapy resistance: opportunities created by adaptive responses to targeted therapies in cancer
Labrie, M., Brugge, J. S., Mills, G. B., & Zervantonakis, I. K. (2022) · Nature Reviews Cancer · doi:10.1038/s41568-022-00454-5 · Cited by 369
Independent Drug Action in Combination Therapy: Implications for Precision Oncology
Plana, D., Palmer, A. C., & Sorger, P. K. (2022) · Cancer Discovery · doi:10.1158/2159-8290.cd-21-0212 · Cited by 307
Self-citationOptogenetic actuator – ERK biosensor circuits identify MAPK network nodes that shape ERK dynamics
Dessauges, C., Mikelson, J., Dobrzyński, M., Jacques, M., Frismantiene, A., Gagliardi, P. A., Khammash, M., & Pertz, O. (2022) · Molecular Systems Biology · doi:10.15252/msb.202110670 · Cited by 48
Velasquez, E., Szadai, L., Zhou, Q., Kim, Y., Pla, I., Sanchez, A., Appelqvist, R., Oskolas, H., Marko‐Varga, M., Lee, B., et al. (2021) · Clinical and Translational Medicine · doi:10.1002/ctm2.466 · Cited by 13
Optogenetic actuator/ERK biosensor circuits identify MAPK network nodes that shape ERK dynamics
Dessauges, C., Mikelson, J., Dobrzyński, M., Jacques, M.-A., Frismantiene, A., Gagliardi, P. A., Khammash, M., & Pertz, O. (2021) · doi:10.1101/2021.07.27.453955 · Cited by 9
Ho, K. K. Y., Srivastava, S., Kinnunen, P. C., Garikipati, K., Luker, G. D., & Luker, K. E. (2023) · Bioengineering · doi:10.3390/bioengineering10020269 · Cited by 8
“Prior research into ERK oscillatory activity has revealed the dynamic nature and integrated feedback loops of signaling networks regulating migration [15–22], proliferation [23], and drug resistance [24].”
BackgroundComputational modeling implicates protein scaffolding in p38 regulation of Akt
Kinnunen, P. C., Luker, G. D., Luker, K. E., & Linderman, J. J. (2022) · Journal of Theoretical Biology · doi:10.1016/j.jtbi.2022.111294 · Cited by 4
Metadata
- Authors
- Gerosa, L., Chidley, C., Fröhlich, F., Sanchez, G., Lim, S. K., Muhlich, J., Chen, J.-Y., Vallabhaneni, S., Baker, G. J., Schapiro, D., Atanasova, M. I., Chylek, L. A., Shi, T., Yi, L., Nicora, C. D., Claas, A., Ng, T. S. C., Kohler, R. H., Lauffenburger, D. A., Weissleder, R., Miller, M. A., Qian, W.-J., Wiley, H. S., & Sorger, P. K.
- Venue
- Cell Systems
- Publisher
- Elsevier BV
- Published
- 2020-11
- Volume
- 11
- Issue
- 5
- Pages
- 478-494.e9
- ISSN
- 2405-4712 (ISSN-L)
- OpenAlex
- W3097920809
- Cited by
- 110
- References
- 23
- FWCI
- 4.43
- Type
- journal article
- Language
- en
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.